This is a multi-center, open-label, safety and efficacy study to assess the use of rhFIX in the treatment and prevention of bleeding in severe and moderate hemophilia B patients who have previously received blood products. It is comprised of three segments: (1) a baseline PK segment, (2) a treatment segment, and (3) a surgical Segment (if appicable). Patients will undergo screening during a 30-day period before the first dose of rhFIX is administered in the Baseline PK Segment.
Showing the most recent 10 out of 782 publications